NCT02654119View on ClinicalTrials.gov

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 11, 2015

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
HER2 Positive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7
Interventions
DRUG

Cyclophosphamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (3)

68118

Nebraska Medicine-Village Pointe, Omaha

68198

University of Nebraska Medical Center, Omaha

68701

Faith Regional Health Services Carson Cancer Center, Norfolk

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER